# EDGAR Filing Document

**Accession Number:** 0000353278
**File Stem:** 0001171843-25-005210
**Filing Date:** 2025-8
**Character Count:** 5943
**Document Hash:** dd2cd9c03d0fefe738813c07474a9a28
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-005210.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001171843-25-005210

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250808

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVO NORDISK A S
- **CENTRAL INDEX KEY:** 0000353278
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-82318
- **FILM NUMBER:** 251196550

**BUSINESS ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000
- **BUSINESS PHONE:** 4544448888

**MAIL ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO NORDISK A/S
- **DATE OF NAME CHANGE:** 19900807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO INDUSTRI A S /DENMARK/
- **DATE OF NAME CHANGE:** 19890811

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

***________________***

**FORM 6-K**

***________________***

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 8, 2025

***________________***

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé 1**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

***________________***

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

![](logo.jpg)

![](ca.jpg)

**Trading in Novo Nordisk shares by board members, executives and associated persons**

**Bagsværd, Denmark, 8 August 2025** — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

Page 2 of 3

---

| | | | |
|:---|:---|:---|:---|
| **1** | **Details of the person discharging managerial responsibilities/person closely associated** | **Details of the person discharging managerial responsibilities/person closely associated** | **Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | Ludovic Helfgott |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares | Shares |
|  | Identification code | Novo Nordisk B DK0062498333 | Novo Nordisk B DK0062498333 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 295.00 | 28710 |
| d) | Aggregated information<br>Aggregated volume Price | <br>28,710 shares<br> DKK 8,469,450.00 | <br>28,710 shares<br> DKK 8,469,450.00 |
| e) | Date of the transaction | 2025-08-07 | 2025-08-07 |
| f) | Place of the transaction | Nasdaq Copenhagen | Nasdaq Copenhagen |

---

 

*Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.*

 

Page 3 of 3

**Contacts for further information**

---

| | |
|:---|:---|
| **Media:** |  |
| **Ambre James-Brown**<br> +45 3079 9289<br> abmo@novonordisk.com | **Liz Skrbkova (US)**<br> +1 609 917 0632<br> lzsk@novonordisk.com |
| **Investors:** |  |
| **Jacob Martin Wiborg Rode**<br> +45 3075 5956<br> jrde@novonordisk.com | **Sina Meyer**<br> +45 3079 6656<br> azey@novonordisk.com |
| **Max Ung**<br> +45 3077 6414<br> mxun@novonordisk.com | **Christoffer Sho Togo Tullin**<br> +45 3079 1471<br> cftu@novonordisk.com |
| **Alex Bruce**<br> +45 3444 2613<br> axeu@novonordisk.com | **Frederik Taylor Pitter**<br> +1 609 613 0568<br> fptr@novonordisk.com |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br>Investor Relations | Novo Allé 1<br>2880 Bagsværd<br>Denmark | Telephone:<br>+45 4444 8888 | <br>www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  |  | Company announcement No 22/ 2025 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 8, 2025 NOVO NORDISK A/S <u>Maziar Mike Doustdar</u> Chief Executive Officer